Convatec Group (CHIX:CTECL) 3-1 Month Momentum %: 5.99% (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:CTECL Convatec Group PLC CHIX:CTECL
82 GF Score
Price £2.30
GF Value £2.56
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Convatec Group 3-1 Month Momentum %?

Convatec Group CHIX:CTECL +1.05% 82 3-1 Month Momentum % is 5.99% as of Aug. 05, 2026. GuruFocus rates CHIX:CTECL with a GF Score™ of 82/100 and a GF Value™ of £2.56 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Convatec Group ranks better than 75.64% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-05), Convatec Group's 3-1 Month Momentum % is 5.99%.

The industry rank for Convatec Group's 3-1 Month Momentum % or its related term are showing as below:

CHIX:CTECl's 3-1 Month Momentum % is ranked better than
75.64% of 854 companies
in the Medical Devices & Instruments industry
Industry Median: -5.795 vs CHIX:CTECl: 5.99

Convatec Group  (CHIX:CTECl) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Convatec Group 3-1 Month Momentum % Related Terms


CHIX:CTECL vs ISRG, BDX, MDLN: 3-1 Month Momentum % Comparison

For the Medical Instruments & Supplies subindustry, Convatec Group's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Convatec Group 3-1 Month Momentum % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Convatec Group's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Convatec Group's 3-1 Month Momentum % falls into.


CHIX:CTECL
82GF Score
Convatec Group PLC CHIX:CTECL
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Convatec Group  (CHIX:CTECl) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of 5.99% mean?
Convatec Group (CHIX:CTECL) has a 3-1 Month Momentum % of 5.99% as of Aug. 05, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Convatec Group and its competitors. According to the industry distribution chart, Convatec Group ranks #208 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 24.4%.
Is Convatec Group's 3-1 Month Momentum % too high?
Convatec Group's current 3-1 Month Momentum % is 5.99%. Based on the distribution chart, Convatec Group ranks #208 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Convatec Group has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Convatec Group's 3-1 Month Momentum % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Convatec Group ranks #208 out of 854 companies for 3-1 Month Momentum %. This places Convatec Group in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Convatec Group and its competitors. Convatec Group's current 3-1 Month Momentum % is 5.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Convatec Group stock overvalued right now?
Based on GuruFocus' analysis, Convatec Group (CHIX:CTECL) is currently considered Modestly Undervalued. The stock's GF Value™ is £2.56, compared to a current price of £2.30 — trading 10.2% below its estimated fair value. The current 3-1 Month Momentum % is 5.99%. Convatec Group's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Convatec Group (CHIX:CTECL), the current 3-1 Month Momentum % is 5.99% as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Convatec Group (CHIX:CTECL) Overvalued in 2026?

Based on GuruFocus' analysis, Convatec Group stock appears to be undervalued. The current stock price of £2.30 is trading 10.2% below its estimated GF Value™ of £2.56. GuruFocus considers Convatec Group to be Modestly Undervalued.

Key valuation signals for CHIX:CTECL:

  • 3-1 Month Momentum %: 5.99%
  • GF Value™: £2.56 vs. price of £2.30 (10.2% below fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the CHIX:CTECL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Convatec Group Business Description

Address 20 Eastbourne Terrace, 7th Floor, London, GBR, W2 6LG
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
82GF Score

Get the complete analysis for CHIX:CTECL

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£2.30
Price
£2.56
GF Value